Skip to main content
SpringerLink
Log in

Gliomas

  • Chapter
  • First Online:
PET and SPECT in Neurology

  • 1318 Accesses

Abstract

Positron emission tomography (PET) is increasingly contributing to diagnosis and management decision in patients with brain tumours and especially gliomas. Through the use of FDG, amino acid tracers ([11C]-methionine, [18F]-fluoro-ethyl-tyrosine and [18F]-fluorodopa) and [18F]-fluorothymidine, PET contributes to diagnosis as well as planning and monitoring of therapy. Amino acid tracers are particularly sensitive for delineating the extent of gliomas and detection of recurrence. They are also being investigated for planning of resection and conformal radiation therapy. Further PET applications include the monitoring and outcome prediction in radiotherapy and chemotherapy and the identification of hypoxic tissue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougere C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 18(9):1199–1208

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bosnyak E, Kamson DO, Robinette NL, Barger GR, Mittal S, Juhasz C (2016) Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI. J Neuro-Oncol 126(2):317–325

    CAS  Google Scholar 

  • Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22(6):633–638

    PubMed  Google Scholar 

  • Ceccon G, Lazaridis L, Stoffels G, Rapp M, Weber M, Blau T, Lohmann P, Kebir S, Herrmann K, Fink GR, Langen K-J, Glas M, Galldiks N (2018) Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. Eur J Nucl Med Mol Imaging 45(9):1626–1635

    PubMed  Google Scholar 

  • Chao ST, Suh JH, Raja S, Lee SY, Barnett G (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96(3):191–197

    CAS  PubMed  Google Scholar 

  • Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M, Newlands ES, Swindell R, Matthews J, Price P (2006) Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 66(2):331–338

    CAS  PubMed  Google Scholar 

  • Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46(6):945–952

    CAS  PubMed  Google Scholar 

  • Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25(30):4714–4721

    CAS  PubMed  Google Scholar 

  • Chiaravalloti A, Esposito V, Ursini F, Di Giorgio E, Zinzi M, Calabria F, Cimini A, Schillaci O (2019) Overall survival and progression-free survival in patients with primary brain tumors after treatment: is the outcome of [18F] FDOPA PET a prognostic factor in these patients? Ann Nucl Med 33(7):471–480

    PubMed  Google Scholar 

  • Cicone F, Filss CP, Minniti G, Rossi-Espagnet C, Papa A, Scaringi C, Galldiks N, Bozzao A, Shah NJ, Scopinaro F, Langen KJ (2015) Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. Eur J Nucl Med Mol Imaging 42(6):905–915

    CAS  PubMed  Google Scholar 

  • Cizek J, Herholz K, Vollmar S, Schrader R, Klein J, Heiss WD (2004) Fast and robust registration of PET and MR images of human brain. NeuroImage 22(1):434–442

    PubMed  Google Scholar 

  • Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E (2012a) FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro-Oncology 14(5):649–657

    CAS  PubMed  PubMed Central  Google Scholar 

  • Colavolpe C, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Figarella-Branger D, Mundler O, Chinot O, Guedj E (2012b) Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. J Neuro-Oncol 107(3):527–535

    Google Scholar 

  • Coope DJ, Cizek J, Eggers C, Vollmar S, Heiss W-D, Herholz K (2007) Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map. J Nucl Med 48:1971–1980

    CAS  PubMed  Google Scholar 

  • De Witte O, Lefranc F, Levivier M, Salmon I, Brotchi J, Goldman S (2001) FDG-PET as a prognostic factor in high-grade astrocytoma. JNeurooncol 49(2):157–163

    Google Scholar 

  • DeLaPaz RL, Patronas NJ, Brooks RA, Smith BH, Kornblith PL, Milam H, Di Chiro G (1983) Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. AJNR Am J Neuroradiol 4(3):826–829

    CAS  PubMed  PubMed Central  Google Scholar 

  • Derlon JM, Petit-Taboue MC, Chapon F, Beaudouin V, Noel MH, Creveuil C, Courtheoux P, Houtteville JP (1997) The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery 40(2):276–288

    CAS  PubMed  Google Scholar 

  • Derlon JM, Chapon F, Noel MH, Khouri S, Benali K, Petit-Taboue MC, Houtteville JP, Chajari MH, Bouvard G (2000) Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 27(7):778–787

    CAS  PubMed  Google Scholar 

  • Dierckx RA, Martin JJ, Dobbeleir A, Crols R, Neetens I, De Deyn PP (1994) Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumours. Eur J Nucl Med 21(7):621–633

    CAS  PubMed  Google Scholar 

  • Dimberg A (2014) The glioblastoma vasculature as a target for cancer therapy. Portland Press, London

    Google Scholar 

  • Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH, Beute GN, Sluimer JD, Slotman BJ, Reijneveld JC, Heimans JJ (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8(9):810–818

    PubMed  Google Scholar 

  • Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO (2015) Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro-Oncology 18(3):426–434

    PubMed  PubMed Central  Google Scholar 

  • Dunkl V, Cleff C, Stoffels G, Judov N, Sarikaya-Seiwert S, Law I, Bogeskov L, Nysom K, Andersen SB, Steiger HJ, Fink GR, Reifenberger G, Shah NJ, Coenen HH, Langen KJ, Galldiks N (2015) The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. J Nucl Med 56(1):88–92

    CAS  PubMed  Google Scholar 

  • Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, O’Sullivan F, Krohn KA (1999) 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 59(3):615–621

    CAS  PubMed  Google Scholar 

  • Filss CP, Cicone F, Shah NJ, Galldiks N, Langen K-J (2017) Amino acid PET and MR perfusion imaging in brain tumours. Clin Transl Imaging 3(5):209–223

    Google Scholar 

  • Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W, Rommel F, Hamacher K, Langen KJ (2006) 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 47(5):776–782

    CAS  PubMed  Google Scholar 

  • Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, Herholz K (2006) Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33(5):516–524

    CAS  PubMed  Google Scholar 

  • Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K, Jacobs AH, Heiss WD (2010a) [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neuro-Oncol 96(2):231–239

    Google Scholar 

  • Galldiks N, Ullrich R, Schroeter M, Fink G, Kracht L (2010b) Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging 37(1):84–92

    PubMed  Google Scholar 

  • Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD (2012) Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med 53(7):1048–1057

    Article  CAS  PubMed  Google Scholar 

  • Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, Ceccon G, Dunkl V, Weinzierl M, Stoffel M, Sabel M, Fink GR, Shah NJ, Langen KJ (2015) The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-Oncology 17(9):1293–1300

    CAS  PubMed  PubMed Central  Google Scholar 

  • Galldiks N, Law I, Pope WB, Arbizu J, Langen K-J (2017) The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. NeuroImage Clin 13:386–394

    Article  PubMed  Google Scholar 

  • Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Dethy S, Brotchi J, Hildebrand J (1997) Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38(9):1459–1462

    CAS  PubMed  Google Scholar 

  • Gomez-Rio M, Rodriguez-Fernandez A, Ramos-Font C, Lopez-Ramirez E, Llamas-Elvira JM (2008) Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging 35(5):966–975

    Article  PubMed  Google Scholar 

  • Gomez-Rio M, Testart Dardel N, Santiago Chinchilla A, Rodriguez-Fernandez A, Olivares Granados G, Luque Caro R, Zurita Herrera M, Chamorro Santos CE, Lardelli-Claret P, Llamas-Elvira JM (2015) 18F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility. Eur J Nucl Med Mol Imaging 42(6):886–895

    Article  CAS  PubMed  Google Scholar 

  • Habermeier A, Graf J, Sandhofer BF, Boissel JP, Roesch F, Closs EI (2015) System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids 47(2):335–344

    Article  CAS  PubMed  Google Scholar 

  • Haroon HA, Buckley DL, Patankar TA, Dow GR, Rutherford SA, Baleriaux D, Jackson A (2004) A comparison of Ktrans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas. J Magn Reson Imaging 19(5):527–536

    Article  PubMed  Google Scholar 

  • Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM (2012) 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro-Oncology 14(8):1079–1089

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, Pietrzyk U (1996) F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 37:1180–1182

    CAS  PubMed  Google Scholar 

  • Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT, Vaalburg W, Franssen EJ (1999) A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 59(10):2411–2416

    CAS  PubMed  Google Scholar 

  • Herholz K (2017) Brain tumors: an update on clinical PET research in gliomas. Semin Nucl Med 47(1):5–17

    Article  PubMed  Google Scholar 

  • Herholz K, Reulen HJ, von Stockhausen HM, Thiel A, Ilmberger J, Kessler J, Eisner W, Yousry TA, Heiss WD (1997) Preoperative activation and intraoperative stimulation of language-related areas in glioma patients. Neurosurgery 41:1253–1262

    Article  CAS  PubMed  Google Scholar 

  • Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, Mendoza G, Weber-Luxenburger G, Lottgen J, Thiel A, Wienhard K, Heiss WD (1998) 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology 50(5):1316–1322

    Article  CAS  PubMed  Google Scholar 

  • Herholz K, Coope D, Jackson A (2007) Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 6(8):711–724

    Article  CAS  PubMed  Google Scholar 

  • Herholz K, Langen KJ, Schiepers C, Mountz JM (2012) Brain tumors. Semin Nucl Med 42(6):356–370

    PubMed  PubMed Central  Google Scholar 

  • Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, Yamaguchi S, Houkin K, Tanaka S, Kuge Y, Tamaki N (2012) (18)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging 39(5):760–770

    Article  CAS  PubMed  Google Scholar 

  • Hirata T, Kinoshita M, Tamari K, Seo Y, Suzuki O, Wakai N, Achiha T, Umehara T, Arita H, Kagawa N, Kanemura Y, Shimosegawa E, Hashimoto N, Hatazawa J, Kishima H, Teshima T, Ogawa K (2019) 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. J Neurosurg 131:676–686

    Article  CAS  PubMed  Google Scholar 

  • Holzer T, Herholz K, Jeske J, Heiss WD (1993) FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 17(5):681–687

    Article  CAS  PubMed  Google Scholar 

  • Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G (2011) O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52(6):856–864

    Article  CAS  PubMed  Google Scholar 

  • Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32(11):1978–1985

    Article  PubMed  PubMed Central  Google Scholar 

  • Janczar K, Su Z, Raccagni I, Anfosso A, Kelly C, Durrenberger PF, Gerhard A, Roncaroli F (2015) The 18-kDa mitochondrial translocator protein in gliomas: from the bench to bedside. Biochem Soc Trans 43(4):579–585

    Article  CAS  PubMed  Google Scholar 

  • Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougere C (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39(6):1021–1029

    Article  CAS  PubMed  Google Scholar 

  • Jansen MH, van Zanten SEMV, Van Vuurden DG, Huisman MC, Vugts DJ, Hoekstra OS, van Dongen GA, Kaspers G-JL (2017) Molecular drug imaging: 89Zr-bevacizumab PET in children with diffuse intrinsic pontine glioma. J Nucl Med 58(5):711–716

    Article  CAS  PubMed  Google Scholar 

  • Juhasz C, Muzik O, Chugani DC, Chugani HT, Sood S, Chakraborty PK, Barger GR, Mittal S (2011) Differential kinetics of alpha-[(11)C]methyl-L-tryptophan on PET in low-grade brain tumors. J Neuro-Oncol 102(3):409–415

    Article  CAS  Google Scholar 

  • Juhasz C, Dwivedi S, Kamson DO, Michelhaugh SK, Mittal S (2014) Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging 13. https://doi.org/10.2310/7290.2014.00015

  • Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, Kirchner PT (1994) Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F- fluorodeoxyglucose PET. AJR 163(6):1459–1465

    Article  CAS  PubMed  Google Scholar 

  • Kapoor GS, Gocke TA, Chawla S, Whitmore RG, Nabavizadeh A, Krejza J, Lopinto J, Plaum J, Maloney-Wilensky E, Poptani H, Melhem ER, Judy KD, O’Rourke DM (2009) Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neuro-Oncol 92(3):373–386

    Article  Google Scholar 

  • Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del FG, Luxen A, Reznik M (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39(5):778–785

    CAS  PubMed  Google Scholar 

  • Kawai N, Maeda Y, Kudomi N, Miyake K, Okada M, Yamamoto Y, Nishiyama Y, Tamiya T (2011) Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 38(3):441–450

    CAS  PubMed  Google Scholar 

  • Khangembam BC, Karunanithi S, Sharma P, Kc SS, Kumar R, Julka PK, Bal C (2014) Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT. Neuroradiology 56(10):893–902

    PubMed  Google Scholar 

  • Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC (2005) 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32(1):52–59

    CAS  PubMed  Google Scholar 

  • Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW, Jung HW, Chang KH (2010) Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 112(9):758–765

    PubMed  Google Scholar 

  • Kiviniemi A, Gardberg M, Frantzen J, Pesola M, Vuorinen V, Parkkola R, Tolvanen T, Suilamo S, Johansson J, Luoto P, Kemppainen J, Roivainen A, Minn H (2015) Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy. EJNMMI Res 5:25

    PubMed  PubMed Central  Google Scholar 

  • Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, Reddin JS, Karp J, Stubbs JB, Hahn SM, Driesbaugh J, Smith D, Prendergast S, Evans SM (2010) Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 37(11):2048–2059

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, Klein JC, Herholz K, Heiss WD (2004) Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 10(21):7163–7170

    CAS  PubMed  Google Scholar 

  • Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM (2005) True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 32(7):663–671

    CAS  PubMed  Google Scholar 

  • Kumar AJ, Leeds NE, Kumar VA, Fuller GN, Lang FF, Milas Z, Weinberg JS, Ater JL, Sawaya R (2010) Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas. J Comput Assist Tomogr 34(4):601–611

    PubMed  Google Scholar 

  • Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, la Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn JC, Kretzschmar HA, Popperl G, Kreth FW (2011) Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology 13(3):307–316

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lam WW, Ng DC, Wong WY, Ong SC, Yu SW, See SJ (2011) Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors-early experience. Clin Neurol Neurosurg 113(2):156–161

    PubMed  Google Scholar 

  • Langen KJ, Herzog H, Kuwert T, Roosen N, Rota E, Kiwit JC, Bock WJ, Feinendegen LE (1988) Tomographic studies of rCBF with [99mTc]-HM-PAO SPECT in patients with brain tumors: comparison with C15O2 continuous inhalation technique and PET. J Cereb Blood Flow Metab 8(6):S90–S94

    CAS  PubMed  Google Scholar 

  • Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen HH, Pauleit D (2006) O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33(3):287–294

    CAS  PubMed  Google Scholar 

  • Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, la Fougere C, Langen KJ, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn JC, Weller M (2019) Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 46(3):540–557

    CAS  PubMed  Google Scholar 

  • Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W (2009) 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol 71(2):242–248

    PubMed  Google Scholar 

  • Leiva-Salinas C, Schiff D, Flors L, Patrie JT, Rehm PK (2017) FDG PET/MR imaging coregistration helps predict survival in patients with glioblastoma and radiologic progression after standard of care treatment. Radiology 283(2):508–514

    PubMed  Google Scholar 

  • Li DL, Xu YK, Wang QS, Wu HB, Li HS (2012) 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. Chin Med J 125(1):91–96

    CAS  PubMed  Google Scholar 

  • Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820

    PubMed  Google Scholar 

  • Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C (2006) Glioma assessment using quantitative blood volume maps generated by T1-weighted dynamic contrast-enhanced magnetic resonance imaging: a receiver operating characteristic study. Acta Radiol 47(3):303–310

    CAS  PubMed  Google Scholar 

  • Maia AC Jr, Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA, Stavale JN (2005) MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26(4):777–783

    PubMed  PubMed Central  Google Scholar 

  • Mapelli P, Incerti E, Bettinardi V, Conte GM, Fallanca F, Bailo M, Vuozzo M, Callea M, Gianolli L, Picchio M (2017) Hypoxia 18F-FAZA PET/CT imaging in lung cancer and high-grade glioma: open issues in clinical application. Clin Transl Imaging 4(5):389–397

    Google Scholar 

  • Masui K, Cloughesy TF, Mischel PS (2012) Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 38(3):271–291

    CAS  PubMed  PubMed Central  Google Scholar 

  • Maurer GD, Brucker DP, Stoffels G, Filipski K, Filss CP, Mottaghy FM, Langen KJ (2020) 18F-FET PET Imaging in differentiating glioma progression from treatment-related changes: a single-center experience. J Nucl Med. 61(4):505–511

    Google Scholar 

  • Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, Mauguen A, Schöder H, Weber WA, Lassman AB, Blasberg R (2019) 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors. Eur J Nucl Med Mol Imaging 47(6):1353–1367

    PubMed  PubMed Central  Google Scholar 

  • Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, Blasberg R (1998) “Facilitated” amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 18(5):500–509

    CAS  PubMed  Google Scholar 

  • Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergstrom M, Eriksson L, Johnstrom P (1989) Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 30(3):225–232

    CAS  PubMed  Google Scholar 

  • Moulin-Romsee G, D’Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, Menten J, Bormans G, Van Laere K (2007) Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging 34(12):2082–2087

    PubMed  Google Scholar 

  • Nioche C, Soret M, Gontier E, Lahutte M, Dutertre G, Dulou R, Capelle L, Guillevin R, Foehrenbach H, Buvat I (2013) Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT. Clin Nucl Med 38(2):81–87

    PubMed  Google Scholar 

  • Oehlke O, Grosu A-L (2017) PET/MRI and brain tumors: focus on radiation oncology treatment planning. Clin Transl Imaging 5(2):159–167

    Google Scholar 

  • Ogawa T, Kanno I, Shishido F, Inugami A, Higano S, Fujita H, Murakami M, Uemura K, Yasui N, Mineura K, Kowada M (1991) Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl- 11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 32(3):197–202

    CAS  PubMed  Google Scholar 

  • Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, Sasaki T (2001) Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 28(11):1664–1670

    CAS  PubMed  Google Scholar 

  • Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neuro-Oncol 64(3):227–237

    CAS  Google Scholar 

  • Pardo FS, Aronen HJ, Fitzek M, Kennedy DN, Efird J, Rosen BR, Fischman AJ (2004) Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res 24(4):2359–2365

    PubMed  Google Scholar 

  • Parent EE, Benayoun M, Ibeanu I, Olson JJ, Hadjipanayis CG, Brat DJ, Adhikarla V, Nye J, Schuster DM, Goodman MM (2018) [18 F]-Fluciclovine PET discrimination between high-and low-grade gliomas. EJNMMI Res 8(1):67

    PubMed  PubMed Central  Google Scholar 

  • Parent EE, Sharma A, Jain M (2019) Amino acid PET imaging of glioma. Curr Radiol Rep 7(5):14

    Google Scholar 

  • Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM (1985) Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62(6):816–822

    CAS  PubMed  Google Scholar 

  • Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, Zilles K, Coenen HH, Langen KJ (2005) O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128(pt 3):678–687

    PubMed  Google Scholar 

  • Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, Tellmann L, Jansen P, Reifenberger G, Hamacher K, Coenen HH, Langen KJ (2009) Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 36(7):779–787

    CAS  PubMed  Google Scholar 

  • Piroth MD, Galldiks N, Pinkawa M, Holy R, Stoffels G, Ermert J, Mottaghy FM, Shah NJ, Langen KJ, Eble MJ (2016) Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. Radiat Oncol 11:87

    PubMed  PubMed Central  Google Scholar 

  • Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, Salmon I, Brotchi J, Levivier M (2004a) Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 101(3):476–483

    CAS  PubMed  Google Scholar 

  • Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, Salmon I, Brotchi J, Levivier M (2004b) Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45(8):1293–1298

    CAS  PubMed  Google Scholar 

  • Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotchi J (2009) Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 64(3):471–481, discussion 481

    PubMed  Google Scholar 

  • Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31(11):1464–1470

    PubMed  Google Scholar 

  • Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34(12):1933–1942

    PubMed  Google Scholar 

  • Potzi C, Becherer A, Marosi C, Karanikas G, Szabo M, Dudczak R, Kletter K, Asenbaum S (2007) [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neuro-Oncol 84(3):305–314

    Google Scholar 

  • Poulsen SH, Urup T, Grunnet K, Christensen IJ, Larsen VA, Jensen ML, Af Rosenschold PM, Poulsen HS, Law I (2017) The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 44(3):373–381

    CAS  PubMed  Google Scholar 

  • Preibisch C, Shi K, Kluge A, Lukas M, Wiestler B, Göttler J, Gempt J, Ringel F, Al Jaberi M, Schlegel J, Meyer B, Zimmer C, Pyka T, Förster S (2017) Characterizing hypoxia in human glioma: a simultaneous multimodal MRI and PET study. NMR Biomed 30(11). https://doi.org/10.1002/nbm.3775

  • Price SJ, Fryer TD, Cleij MC, Dean AF, Joseph J, Salvador R, Wang DD, Hutchinson PJ, Clark JC, Burnet NG, Pickard JD, Aigbirhio FI, Gillard JH (2009) Imaging regional variation of cellular proliferation in gliomas using 3′-deoxy-3′-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Clin Radiol 64(1):52–63

    CAS  PubMed  Google Scholar 

  • Prieto E, Marti-Climent JM, Dominguez-Prado I, Garrastachu P, Diez-Valle R, Tejada S, Aristu JJ, Penuelas I, Arbizu J (2011) Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation. J Nucl Med 52(6):865–872

    PubMed  Google Scholar 

  • Rachinger W, Goetz C, Popperl G, Gildehaus FJ, Kreth FW, Holtmannspotter M, Herms J, Koch W, Tatsch K, Tonn JC (2005) Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57(3):505–511, discussion 505–511

    PubMed  Google Scholar 

  • Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY (2011) Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology 13(3):353–361

    PubMed  PubMed Central  Google Scholar 

  • Ribom D, Smits A (2005) Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas. Neurol Res 27(5):516–521

    PubMed  Google Scholar 

  • Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP (1998) Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? [see comments]. AJNR Am J Neuroradiol 19(3):407–413

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sacconi B, Raad RA, Lee J, Fine H, Kondziolka D, Golfinos JG, Babb JS, Jain R (2016) Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging. J Neuro-Oncol 127(2):287–293

    CAS  Google Scholar 

  • Scherer HJ (1940) The forms of growth in gliomas and their practical significance. Brain 63(1):1–35

    Google Scholar 

  • Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Popperl G, Holtmannspotter M, Kretzschmar HA, Kessler H, Tonn JC, Schwaiger M, Beer AJ (2009) Imaging of integrin {alpha}v{beta}3 expression in patients with malignant glioma by [18F]galacto-RGD positron emission tomography. Neuro Oncol 11(6):861–870

    PubMed  PubMed Central  Google Scholar 

  • Sharma R, Kallur KG, Ryu JS, Parameswaran RV, Lindman H, Avril N, Gleeson FV, Lee JD, Lee KH, O’Doherty MJ, Groves AM, Miller MP, Somer EJ, Coombes CR, Aboagye EO (2015) Multicenter reproducibility of 18F-fluciclatide PET imaging in subjects with solid tumors. J Nucl Med 56(12):1855–1861

    CAS  PubMed  Google Scholar 

  • Shi X, Liu Y, Zhang X, Yi C, Wang X, Chen Z, Zhang B (2013) The comparison of 13N-ammonia and 18F-FDG in the evaluation of untreated gliomas. Clin Nucl Med 38(7):522–526

    PubMed  Google Scholar 

  • Shibahara I, Kumabe T, Kanamori M, Saito R, Sonoda Y, Watanabe M, Iwata R, Higano S, Takanami K, Takai Y, Tominaga T (2010) Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog. J Neurosurg 113(2):358–368

    CAS  PubMed  Google Scholar 

  • Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4(11):1334–1336

    CAS  PubMed  Google Scholar 

  • Shinoura N, Nishijima M, Hara T, Haisa T, Yamamoto H, Fujii K, Mitsui I, Kosaka N, Kondo T, Hara T (1997) Brain tumors: detection with C-11 choline PET. Radiology 202(2):497–503

    CAS  PubMed  Google Scholar 

  • Shinozaki N, Uchino Y, Yoshikawa K, Matsutani T, Hasegawa A, Saeki N, Iwadate Y (2011) Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. J Neurosurg 114(6):1640–1647

    PubMed  Google Scholar 

  • Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC (2009) Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 192(2):W45–W52

    PubMed  Google Scholar 

  • Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T (1998) Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 38(6):342–347

    CAS  Google Scholar 

  • Spence AM, Muzi M, Mankoff DA, O’Sullivan SF, Link JM, Lewellen TK, Lewellen B, Pham P, Minoshima S, Swanson K, Krohn KA (2004) 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 45(10):1653–1659

    PubMed  Google Scholar 

  • Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL, Krohn KA (2008) Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 14(9):2623–2630

    CAS  PubMed  PubMed Central  Google Scholar 

  • Spence AM, Muzi M, Link JM, O’Sullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA (2009) NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3′-deoxy-3′-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol 11(5):343–355

    PubMed  PubMed Central  Google Scholar 

  • Su Z, Roncaroli F, Durrenberger PF, Coope DJ, Karabatsou K, Hinz R, Thompson G, Turkheimer FE, Janczar K, Du Plessis D, Brodbelt A, Jackson A, Gerhard A, Herholz K (2015) The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)PK11195 PET imaging and neuropathology study. J Nucl Med 56(4):512–517

    CAS  PubMed  Google Scholar 

  • Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, Adamsen TC, Krohn KA, Spence AM (2009) Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 50(1):36–44

    PubMed  Google Scholar 

  • Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, Di Chiro G (1997) Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 87(4):516–524

    CAS  PubMed  Google Scholar 

  • van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE (2015) Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 19:1–12

    PubMed  Google Scholar 

  • Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K (2008) Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49(5):694–699

    PubMed  Google Scholar 

  • Thompson TP, Lunsford LD, Kondziolka D (1999) Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. StereotactFunctNeurosurg 73(1–4):9–14

    CAS  Google Scholar 

  • Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily RC, Hummel S, Scharnhorst J, Krohn KA, Spence AM (2002) Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 43(12):1667–1673

    PubMed  Google Scholar 

  • Trigonis I, Jackson A (2010) Imaging pharmacodynamics in oncology: the potential significance of “flares”. Ann Nucl Med 24(3):137–147

    Article  CAS  PubMed  Google Scholar 

  • Tripathi M, Sharma R, D’Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A (2009) Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 34(12):878–883

    Article  PubMed  Google Scholar 

  • Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Nishikawa M, Ohata K, Torii K, Morino M, Nishio A, Hara M (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma. Ann Nucl Med 18(4):291–296

    Article  CAS  PubMed  Google Scholar 

  • Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, Neumaier B, Heiss WD, Wienhard K, Jacobs AH (2008) Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 14(7):2049–2055

    Article  CAS  PubMed  Google Scholar 

  • Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, Deckert M, Heiss WD, Jacobs AH (2009) Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 50(12):1962–1968

    Article  PubMed  Google Scholar 

  • Unterrainer M, Fleischmann DF, Diekmann C, Vomacka L, Lindner S, Vettermann F, Brendel M, Wenter V, Ertl-Wagner B, Herms J, Wetzel C, Rupprecht R, Tonn JC, Belka C, Bartenstein P, Niyazi M, Albert NL (2019) Comparison of (18)F-GE-180 and dynamic (18)F-FET PET in high grade glioma: a double-tracer pilot study. Eur J Nucl Med Mol Imaging 46(3):580–590

    Article  PubMed  Google Scholar 

  • Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK (1988) PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 69(6):830–838

    Article  CAS  PubMed  Google Scholar 

  • Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF (1992) Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 33(12):2133–2137

    CAS  PubMed  Google Scholar 

  • Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L (2005) Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 32(1):39–51

    Article  CAS  PubMed  Google Scholar 

  • Verheijen RB, Yaqub M, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH (2018) Molecular imaging of ABCB1 and ABCG2 inhibition at the human blood–brain barrier using Elacridar and 11C-Erlotinib PET. J Nucl Med 59(6):973–979

    CAS  PubMed  Google Scholar 

  • Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch 447(5):532–542

    CAS  PubMed  Google Scholar 

  • Viel T, Talasila KM, Monfared P, Wang J, Jikeli JF, Waerzeggers Y, Neumaier B, Backes H, Brekka N, Thorsen F, Stieber D, Niclou SP, Winkeler A, Tavitian B, Hoehn M, Bjerkvig R, Miletic H, Jacobs AH (2012) Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI. J Nucl Med 53(7):1135–1145

    CAS  PubMed  Google Scholar 

  • Villani V, Carapella CM, Chiaravalloti A, Terrenato I, Piludu F, Vidiri A, Schillaci O, Floris R, Marzi S, Fabi A, Pace A (2015) The role of PET [18F]FDOPA in evaluating low-grade glioma. Anticancer Res 35(9):5117–5122

    CAS  PubMed  Google Scholar 

  • Waldman AD, Jackson A, Price SJ, Clark CA, Booth TC, Auer DP, Tofts PS, Collins DJ, Leach MO, Rees JH (2009) Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol 6(8):445–454

    CAS  PubMed  Google Scholar 

  • Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J (2012) Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician’s perspective. J Nucl Med 53(3):393–398

    CAS  PubMed  Google Scholar 

  • Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stocklin G, Schwaiger M (2000) O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 27(5):542–549

    CAS  PubMed  Google Scholar 

  • Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bartschi E, Buettner UW, Roelcke U (2009) Early metabolic responses in temozolomide treated low-grade glioma patients. J Neuro-Oncol 95(1):87–93

    CAS  Google Scholar 

  • Zhao F, Cui Y, Li M, Fu Z, Chen Z, Kong L, Yang G, Yu J (2014) Prognostic value of 3′-deoxy-3′-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas. Nucl Med Biol 41(8):710–715

    CAS  PubMed  Google Scholar 

  • de Zwart PL, van Dijken BRJ, Holtman GA, Stormezand GN, Dierckx RA, van Laar PJ, van der Hoorn A (2019) Diagnostic accuracy of positron emission tomography tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and meta-analysis. J Nucl Med 61(4):498–504

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Manchester, Division of Neuroscience and Experimental Psychology, Manchester, UK

    Karl Herholz

Authors
  1. Karl Herholz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Herholz .

Editor information

Editors and Affiliations

  1. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Rudi A. J. O. Dierckx

  2. Faculty of Electrical Engineering, Medical Engineering and Computer Science, Offenburg University, Offenburg, Germany

    Andreas Otte

  3. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Erik F. J. de Vries

  4. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Aren van Waarde

  5. Neurology, University Medical Center Groningen, Groningen, The Netherlands

    Klaus L. Leenders

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Herholz, K. (2021). Gliomas. In: Dierckx, R.A.J.O., Otte, A., de Vries, E.F.J., van Waarde, A., Leenders, K.L. (eds) PET and SPECT in Neurology. Springer, Cham. https://doi.org/10.1007/978-3-030-53168-3_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53168-3_39

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53167-6

  • Online ISBN: 978-3-030-53168-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation